Vividion Therapeutics, Inc.

Based in California, US, and founded in 2017, Vividion Therapeutics, Inc. operates as a biotechnology company that develops small molecule medicines that help patients with cancer and immune disorders. The was founded by Benjamin Cravatt, Jin-Quan Yu, and Phil Baran and has 105 employees as of July 2021. In February 2021, the firm received USD 135 million in Series C funding from Boxer Capital, Logos Capital Partners, SB Investment Advisers, and Woodline Partners.

In August 2021, Vividion Therapeutics was acquired by Bayer AG for USD 1. 5 billion. The company filed for IPO in July 2021 and raised USD 100 million. Vividion Therapeutics, Inc.

develops novel drug discovery platforms that focus on identifying undruggable targets for cancer. The company's platform has 3 main components: a novel chemoproteomic screening technology, an integrated data portal and a proprietary chemistry library. The firm's platform develops a variety of small molecule therapies across indications, with an initial focus on targets relevant to oncology and immunology. The company also provides NRF2 Program, STAT3 Program, and Werner (WRN) Program for various inflammatory diseases such as irritable bowel disease and others.

The company generates revenue from collaboration agreements and as of March 2021, Vividion Therapeutics, Inc. has generated USD 14,941 in the first quarter of 2021. Vividion Therapeutics, Inc. plans to use its funding from IPO as of August 2021 to advance its diversified pipeline of small molecule therapeutics in oncology and immunology, expand its custom-built library of chemical scaffolds and CRGs, and hire additional personnel to build organizational talent, capital expenditures and the costs of operating as a public company.

The company plans to submit its first Investigational New Drug (IND) in 2022.